Carlson J A, Day T G, Allegra J C, Woodcock T M, Greenberg R A, Masterson B J
Cancer. 1984 Jul 15;54(2):211-4. doi: 10.1002/1097-0142(19840715)54:2<211::aid-cncr2820540206>3.0.co;2-e.
Twenty-three patients with recurrent unresectable carcinoma of the cervix or distant metastasis at initial presentation were treated with methyl-CCNU (175 mg/m2) and doxorubicin (45 mg/m2) on day 1 and cis- diamminedichloroplatinum II (90 mg/m2) on day 22 of a 42-day treatment cycle. Twenty-two patients had squamous carcinoma and 1 had adenosquamous carcinoma. There were two complete responses (CR), five partial responses (PR) (greater than 50% tumor reduction, greater than 3-month duration), four patients with stable disease (less than 50% reduction, greater than 3-month duration), and 12 patients who had tumor progression. One CR has been maintained greater than 28 months, and the other greater than 8 months. Total CR and PR was 7 of 23 (30.4%). Three 23 responses occurred among 15 patients (20%) who had cancer primarily confined to the pelvis, while 4 of 8 patients (50%) with distant metastasis responded. During the initial 2 cycles of chemotherapy, 12 patients had myelosuppression, defined as a leukocytes less than 3000/mm3, granulocytes less than 1,000/mm3, or platelets less than 100,000/mm3. There were no treatment-related deaths.
23例初诊时为复发性不可切除宫颈癌或远处转移的患者，在42天治疗周期的第1天接受甲环亚硝脲（175mg/m²）和阿霉素（45mg/m²）治疗，在第22天接受顺式二氨基二氯铂II（90mg/m²）治疗。22例为鳞状细胞癌，1例为腺鳞癌。有2例完全缓解（CR），5例部分缓解（PR）（肿瘤缩小超过50%，持续时间超过3个月），4例疾病稳定（缩小小于50%，持续时间超过3个月），12例肿瘤进展。1例CR维持超过28个月，另1例超过8个月。总CR和PR为23例中的7例（30.4%）。15例主要局限于盆腔的癌症患者中有3例（20%）出现缓解，而8例远处转移患者中有4例（50%）有反应。在化疗的最初2个周期中，12例患者出现骨髓抑制，定义为白细胞低于3000/mm³、粒细胞低于1000/mm³或血小板低于100000/mm³。无治疗相关死亡。
